Posts tagged ‘urologic cancers’


Bladder cancer patient and fitness instructor can still wear a bikini

August 19, 2014 | by

Christine Crews isn’t only a fitness enthusiast, she’s also a personal trainer and fitness instructor. Being active defines her life. So when she was diagnosed with bladder cancer at age 30, she decided she absolutely couldn’t let the disease interfere with that lifestyle.

And it didn’t. For the next 15 years, Crews continued to run marathons, teach fitness classes and train 20 to 30 clients a week, all while fighting her bladder cancer with chemotherapy and periodic tumor removals.

By the age of 45, however, the cancer had spread to 80 percent of her bladder. She was told she would need a cystectomy, that is, the surgical removal of her bladder. » Continue Reading


Second opinion: A cancer surgeon shares his perspective and advice

July 23, 2014 | by

Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year.

medical chart and second opinions

Diagnosed with cancer? Get a second opinion at an expert research and treatment center like City of Hope. Clayton Lau, M.D., explains why it could save your life.

With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Agency for Healthcare Quality and Research recently noted in calling attention to the diagnostic errors research.

This means that patients who’ve been diagnosed with cancer shouldn’t always assume that either the diagnosis or their options are precisely what they’ve been told. Sometimes a cancer has progressed more than the diagnostic tests suggest; sometimes it’s progressed less. And sometimes the diagnosis is completely off-base.

Clayton S. Lau, M.D., associate clinical professor and an expert in testicular cancer surgery at City of Hope, explains the difference that second opinions can make in getting a proper cancer diagnosis and care. » Continue Reading


Bladder cancer patient finds he has an alternative to external device

July 9, 2014 | by

When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life.

Neobladder

An artificial bladder, called a neobladder, enables patients to urinate normally, eliminating the need for an external bag and allowing patients to transition back to their normal life after surgery.

“My first response was ‘I don’t want to live like that,” Querido told ABC 7 in a recent interview. “That’s gonna be a terrible way to live.”

Querido simply couldn’t accept that collecting his urine externally was his only option. The Thousand Oaks resident and his wife decided to get a second opinion at City of Hope. There, they learned there was indeed another choice: an artificial bladder, called a neobladder, built by specialists at City of Hope. » Continue Reading


Meet our doctors: Urologist Jonathan Yamzon on curing testicular cancer

May 31, 2014 | by

Testicular cancer is the most common form of cancer in men 15 to 34 years old. Yet it accounts for only 1 percent of all cancers in men in the United States. According to the American Cancer Society, about 8,800 men are diagnosed with testicular cancer each year, and about 380 men die of the disease. However, if detected early, the disease has an overall five-year survival rate of 96 percent. For Stage 1 patients, the five-year survival rate is an astonishing 99 percent.

Although rare, testicular cancer is one of the most curable forms of cancer says Dr. Jonathan Yamzon.

Although rare, testicular cancer is one of the most curable forms of cancer, says City of Hope’s Jonathan Yamzon.

Here, urologist Jonathan Yamzon, M.D., assistant clinical professor and surgeon in City of Hope’s Division of Urology and Urologic Oncology, discusses how early detection and the use of advanced treatment options can help cure men of this rare disease and allow them to lead healthy, normal lives.

What is testicular cancer?

Testicular cancer occurs when cells in the testicles grow and multiply uncontrollably, damaging surrounding tissue and interfering with the normal function of the testicle. If the disease spreads, it is still called testicular cancer.

The most common types of testicular cancer form in germ cells, where sperm is made. They fall into two categories: seminomas and nonseminomas. Seminomas are slow-growing and tend to stay within the testicle. Nonseminomas are faster-growing, tend to spread outside the testicle and strike younger men. More than 90 percent of testicular cancers begin in the germ cells. » Continue Reading


Meet our doctors: Philip Pearson and David Rhodes on active surveillance

April 5, 2014 | by

Cancer of the prostate is the No. 2 cancer killer of men, behind lung cancer, accounting for more than 29,000 deaths annually in this country. But because prostate cancer advances slowly, good prostate health and early detection can make all the difference.

Many prostate cancer tumors don’t require immediate treatment because they’re small, confined and slow-growing. For patients with these type of tumors, so-called “watchful waiting,” increasingly known as “active surveillance” may be the best course of action. In “active surveillance,” physicians closely monitor patients so they can identify early signs of disease progression and treat the cancer before it spreads outside the prostate.

David Rhodes, M.D.

David Rhodes

Philip Pearson, M.D.

Philip Pearson

Here, Philip G. Pearson, M.D., and David W. Rhodes, M.D., of City of Hope | Pasadena, provide simple strategies that can help men better understand this important gland. They also explain why active surveillance is becoming a more common prostate cancer management option. » Continue Reading


Urologic cancers: Dispatches from research’s front lines

March 28, 2014 | by

Urologic cancers, including prostate cancer, kidney cancer and bladder cancer, are diagnosed in more than 381,000 Americans each year, and almost 60,000 people die from the diseases. City of Hope’s physicians and scientists are determined to reduce those numbers.

Our groundbreaking research holds the promise of better treatments and cures for the millions of people worldwide battling these difficult cancers. The Division of Urology and Urologic Oncology, led by Timothy Wilson, M.D., Pauline & Martin Collins Family Chair in Urology and director of the Prostate Cancer Program, report the following developments in the treatment of urologic cancers.

**

Overcoming drug resistance in metastatic prostate cancer

African American men are 60 percent more likely than white men to get prostate cancer and 2.4 times more likely to die of the disease.

The drug pyrvinium shows promise in the treatment of prostate cancer. Even better, it doesn’t target testosterone.

When prostate cancer metastasizes, it is signaled to grow by a protein called the androgen receptor, which is activated by testosterone. Many men initially respond to hormone treatments that inhibit testosterone, but prostate cancer cells adapt and develop resistance to these therapies, and the cancer almost always returns.

Jeremy Jones, Ph.D., assistant professor of Molecular Pharmacology, found that pyrvinium, a drug used for decades to treat pinworm infections, could treat metastatic prostate cancer without targeting testosterone. Pyrvinium works by inhibiting the DNA binding domain – a different part of the androgen receptor that’s activated when testosterone is blocked –  and could be effective when all other therapies have failed. Jones is testing pyrvinium derivatives in cell cultures and mice, and his goal is to reach phase I clinical trial in the next two years.

Jones is also working with Cy Stein, M.D., Ph.D., Arthur & Rosalie Kaplan Chair of Medical Oncology, to combine the action of two drugs, enzalutamide and abiraterone, to treat prostate cancer that is resistant to hormone therapy. They have designed a compound called COH11023 that inhibits the production of testosterone, prevents testosterone from binding to the androgen receptor and breaks down the androgen receptor to rid the cancer cells of the protein. » Continue Reading


Appendix rupture led to surprise diagnosis of kidney cancer (VIDEO)

March 20, 2014 | by

“One day I had a pain in my side and ended up having my appendix rupture. During that time of the appendix rupturing, they discovered I had a large tumor covering most of my kidney,” said Joelle Hood, a learning center principal and a certified life coach.

Hood’s doctor referred her to City of Hope, where she met urologic oncology specialist Clayton Lau, M.D., an assistant clinical professor. They discussed the best treatment option for her cancer and took it day by day from there.

» Continue Reading


Kidney cancer rates are rising: Expert explains risks, outcomes

March 1, 2014 | by

Many cancer incidence rates decline over time, but kidney cancer is one of the few cancers with incidence rates that continue to rise year after year. 

kidneys

Kidney cancer is on the rise. A City of Hope expert explores the risks and the treatments.

Currently, nearly 64,000 new cases of kidney cancer are diagnosed in the United States each year, and approximately 13,860 people die from it, according to the American Cancer Society. Men are much more likely than women to be diagnosed with the disease and to die from it.

But unlike other cancers, there is no formalized way to detect kidney cancer, which is why it’s important to know the disease’s risk factors and symptoms. Here Sumanta Kumar Pal, M.D., co-director of the Kidney Cancer Program at City of Hope, explores both the factors behind the rise in kidney cancer and the disease’s current treatments.

While most cancer incident rates continue to drop each year, kidney cancer is one of the few that continue to increase. Why is this?

Unlike breast cancer or colon cancer, kidney cancer is a disease for which we have no good screening modalities. At the moment, there’s no formalized way to actually detect kidney cancer before the onset of the disease. But as time has gone on, our imaging modalities have gotten better and better  — what I’m referring to here are CT scans and MRIs — and as that happened, we’ve found more and more incidental diagnosis of kidney cancer. » Continue Reading


Future kidney cancer treatments show promise (w/VIDEO)

December 21, 2013 | by

Treatments for kidney cancer have improved dramatically over the past few years — particularly for renal cell carcinoma, the most common type of kidney cancer. And the future looks bright as well.

kidneys

Treatment for cancer of the kidneys (shown here) is improving, with more advances expected.

The Food and Drug Administration has approved seven new drugs for the treatment of renal cell carcinoma, especially significant because it approved only one drug between 1992 and 2005. Further, targeted therapies are improving standard care for patients with the disease, and several promising studies could lead to new treatment advances.

Sumanta Kumar Pal, M.D., co-director of the Kidney Cancer Program at City of Hope, summed up the field in a recent interview with OncLive. “This is so incredibly promising for patients and their families,” he said of the recent developments.

But, as with most cancer treatments, new, innovative approaches are always needed. » Continue Reading


Meet our doctors: Surgeon Jennifer Linehan on prostate cancer

December 7, 2013 | by

City of Hope surgeon Jennifer Linehan, M.D.

Jennifer Linehan, M.D., says exercising and eating a healthy diet are key in lowering the risk for prostate cancer.

Prostate cancer is one of the most common types of cancer affecting men, with one in six American men receiving the diagnosis in their lifetime. In most cases, the disease grows slowly and causes no problems. But some prostate cancers are fast-moving and lethal, causing more than 29,000 deaths annually because the disease wasn’t detected and treated in time. 

Here Jennifer Linehan, M.D., a surgeon on City of Hope’s renowned urology and urologic oncology program team, clears up confusion about using prostate-specific antigen (PSA) tests to screen for the disease, and how technology plays a role in some of the newest advanced prostate cancer treatment options available.   

» Continue Reading